Zevra Therapeutics, Inc.
ZVRA
$8.33
-$0.06-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 84.39M | 62.02M | 40.59M | 23.61M | 24.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.39M | 62.02M | 40.59M | 23.61M | 24.49M |
| Cost of Revenue | 16.33M | 17.39M | 8.59M | 7.42M | 7.28M |
| Gross Profit | 68.06M | 44.63M | 32.00M | 16.20M | 17.21M |
| SG&A Expenses | 73.44M | 72.71M | 64.53M | 54.92M | 54.18M |
| Depreciation & Amortization | 5.16M | 6.39M | 6.32M | 6.24M | 5.39M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.35M | 122.43M | 112.47M | 110.62M | 111.23M |
| Operating Income | -28.96M | -60.41M | -71.88M | -87.00M | -86.74M |
| Income Before Tax | 53.64M | 21.40M | -75.37M | -90.14M | -89.66M |
| Income Tax Expenses | 18.32M | 18.75M | 16.62M | 15.37M | 0.00 |
| Earnings from Continuing Operations | 35.33 | 2.64 | -91.99 | -105.51 | -89.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.33M | 2.64M | -91.99M | -105.51M | -89.66M |
| EBIT | -28.96M | -60.41M | -71.88M | -87.00M | -86.74M |
| EBITDA | -23.62M | -53.85M | -65.40M | -80.61M | -81.22M |
| EPS Basic | 0.53 | -0.15 | -1.90 | -2.24 | -2.08 |
| Normalized Basic EPS | -0.42 | -0.84 | -0.99 | -1.22 | -1.30 |
| EPS Diluted | 0.50 | -0.19 | -1.90 | -2.24 | -2.09 |
| Normalized Diluted EPS | -0.41 | -0.84 | -0.99 | -1.22 | -1.30 |
| Average Basic Shares Outstanding | 218.30M | 210.16M | 197.28M | 184.96M | 170.20M |
| Average Diluted Shares Outstanding | 219.85M | 211.70M | 197.28M | 184.96M | 170.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |